FDA Extends PDUFA Date for VIVUS's (VVUS) Qnexa NDA to July 17th
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
The U.S. FDA informed VIVUS (Nasdaq: VVUS) of an extended Prescription Drug User Fee Act (PDUFA) date for its review of the Qnexa New Drug Application (NDA) from April 17 to July 17, 2012. The three-month extension is a standard extension period.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Solowin Holdings marks 10 years, expands into stablecoins and AI
- Amplitude Therapeutics signs taRNA vaccine deal with Eli Lilly
Create E-mail Alert Related Categories
Corporate News, FDA, Hot Corp. News, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
